Products & ReviewLife Sciences
CD19
A recombinant B-lymphocyte surface antigen, CD19, which is a pivotal target for immunotherapy in B-cell malignancies, including CAR-T cell and antibody-based therapies.
CD19
Request Pricing
Receive your quote directly from the manufacturer.
CD19 is a cell surface protein expressed throughout B-cell development and on most B-cell neoplasms, but not on hematopoietic stem cells. This makes it an ideal target for therapies against B-cell leukemias and lymphomas. Our recombinant CD19 protein is widely used for CAR-T validation, antibody screening, and research.
Key Features & Benefits:
- High Purity and Authentic Glycosylation (from Mammalian Cells)
- Binds Validated Anti-CD19 Antibodies and CARs
- Multiple Formats: His-tag, Fc-fusion, etc.
- Functional in Cell-Based Assays
Relevant Applications:
- CAR-T Cell Functional Validation and Potency Assays
- Anti-CD19 Antibody Screening and Characterization
- Study of B-cell Development and Activation
- Biomarker for B-cell Malignancies
